Skip to main content
Article thumbnail
Location of Repository

Maternal Caffeine Consumption and its Relationship to Adverse Pregnancy Outcomes

By Neelam Potdar

Abstract

There are conflicting reports about the association of maternal caffeine intake with adverse pregnancy outcomes, specifically fetal growth restriction (FGR). Differences in study design and exposure definition have been partly responsible. In order to study the association between maternal caffeine consumption and FGR, I prospectively quantified caffeine intake in pregnancy from all known sources, assessed caffeine metabolism in pregnancy and used serial ultrasound growth scans to identify FGR fetus.\ud In a prospective study of 1340 pregnant women in Leicestershire, UK, I quantified total caffeine intake from 4-weeks prior and throughout pregnancy using a validated caffeine assessment tool. Caffeine half-life (used here as proxy for clearance) was determined by measuring caffeine in saliva after a caffeine challenge. The primary outcome measure was FGR, which was determined by customised birth weight centile calculator and in a subgroup by serial ultrasound growth scan.\ud Mean caffeine consumption decreased in the 1st and then increased in the 3rd trimester. Caffeine consumption throughout pregnancy was associated with an increased risk of FGR: OR = 1.2 (95% CI, 0.9 to 1.6) for 100-199 mg/day, OR = 1.5 (1.1 to 2.1) for 200- 299 mg/day, and OR = 1.4 (1.0 to 2.0) for over 300 mg/day compared to < 100 mg/day (Ptrend< 0.001). There was some evidence that the effect of caffeine on FGR was strongest in women with faster caffeine clearance (P = 0.06). On comparing outcome measure of FGR as defined by serial ultrasound growth scans in pregnancy and customised centile calculator, there was a moderate degree of agreement between the two methods (κ = 0.38, CI 0.26, 0.49).\ud Caffeine consumption during pregnancy is associated with an increased risk of FGR and this effect is continuous throughout pregnancy. This effect was observed from four weeks before pregnancy and was statistically significant in the first trimester. A public health recommendation for pregnant women would be to reduce or limit the caffeine intake to a maximum of 2 cups of tea/coffee per day. Future research is required to study the mechanistic effect of caffeine on trophoblastic tissue

Publisher: University of Leicester
Year: 2010
OAI identifier: oai:lra.le.ac.uk:2381/8325

Suggested articles

Citations

  1. (1988). A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking.
  2. (2001). A longitudinal study of quantitative uterine blood flow with the use of color power angiography in appropriate for gestational age pregnancies.
  3. (1990). A rapid gas-liquid chromatographic method for the determination of cotinine and nicotine in biological fluids.
  4. (1990). A review of the use of saliva cotinine as a marker of tobacco smoke exposure. Prev Med
  5. (1992). A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
  6. (1998). A smoking cessation programme conducted through dental practices in the UK. Br Dent
  7. (1995). A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer.
  8. (1957). A study of the metabolism of theobromine, theophylline, and caffeine in man.
  9. (1983). A study of the teratogenic potential of caffeine ingested in drinking-water.
  10. (2004). A Textbook of Modern Toxicology. Ed: Ernest Hodgson. Wiley Interscience,
  11. (1987). A urinary metabolite ratio that reflects systemic caffeine clearance.
  12. (1994). Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test.
  13. (1990). Activities of caffeine, theophylline, and enprofylline analogs as tracheal relaxants.
  14. (1981). Adenosine receptors and behavioral actions of methylxanthines.
  15. (1982). Adenosine receptors: targets for future drugs.
  16. (2000). Adult functional outcome of those born small for gestational age: twenty-six-year follow-up of the 1970 British Birth Cohort.
  17. (1999). Alcohol and pregnancy.
  18. (1997). Alcohol consumption and pregnancy in the Mexican national addiction survey.
  19. (2008). Alcohol consumption during pregnancy and the risk of early stillbirth among singletons.
  20. (1988). Alcohol consumption in Dundee primigravidas and its effects on outcome of pregnancy.
  21. (2005). Alcohol teratogenesis: mechanisms of damage and strategies for intervention. Exp Biol Med
  22. (1987). Alcohol teratogenicity in the human: a detailed assessment of specificity, critical period, and threshold.
  23. (1987). Antagonism of the cardiovascular effects of adenosine by caffeine or 8-(p-sulfophenyl)theophylline.
  24. (1984). Antagonistic effect of theophylline on the adenosine-induced decreased in renin release.
  25. (1984). Antibody assays for varicella-zoster virus: comparison of competitive enzyme-linked immunosorbent assay (ELISA), competitive radioimmunoassay (RIA), complement fixation, and indirect immunofluorescence assays.
  26. (2001). Apoptosis in the placenta of pregnancies complicated with IUGR.
  27. (2004). Apoptosis in the Trophoblast—Role of Apoptosis in Placental Morphogenesis.J Soc Gyne Inves.2004; 11: 353-362 Ikena
  28. (1974). Are coffee and alcohol consumption risk factors in pregnancy? (author's transl).
  29. (2008). Assessing caffeine exposure in pregnant women.
  30. (1986). Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.
  31. (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97(3):125-134.
  32. (2003). Association of maternal caffeine consumption with decrements in fetal growth.
  33. (1999). Associations between maternal decaffeinated and caffeinated coffee consumption and fetal growth and gestational duration.
  34. (2004). Beverage caffeine intake in US consumers and subpopulations of interest: estimates from the Share of Intake Panel survey.
  35. (1992). Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms.
  36. (1992). Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.
  37. (1987). Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarboninducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15(2):237-249.
  38. (1993). Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones.
  39. (1993). Birth weight from pregnancies dated by ultrasonography in a multicultural British population.
  40. (1999). Birth weight in relation to morbidity and mortality among newborn infants.
  41. (1989). Caffeinated beverages and low birthweight: a casecontrol study.
  42. (1977). Caffeine - its direct and indirect influence on reproduction.
  43. (1988). Caffeine and cardiac arrhythmias.
  44. (2008). Caffeine and miscarriage risk.
  45. (1977). Caffeine and pregnancy - retrospective survey.
  46. (1989). Caffeine and regional brain monoamine utilization in mice.
  47. (1991). Caffeine and spontaneous abortion of known karyotype.
  48. (1981). Caffeine and the fetus: is trouble brewing?
  49. (1981). Caffeine antagonizes several central effects of diazepam.
  50. (1991). Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.
  51. (1994). Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
  52. (1992). Caffeine as a probe for human cytochromes P450: validation using cDNAexpression, immunoinhibition and microsomal kinetic and inhibitor techniques.
  53. (1980). Caffeine as an intensifier of stress-induced hormonal and pathophysiologic changes in mice.
  54. (1973). Caffeine as teratogen and mutagen.
  55. (1991). Caffeine clearance by enzyme multiplied immunoassay technique: a simple, inexpensive, and useful indicator of liver function.
  56. (1986). Caffeine consumption during pregnancy and association with late spontaneous abortion.
  57. (1991). Caffeine consumption during pregnancy and fetal growth.
  58. (1985). Caffeine elimination: a test of liver function.
  59. (2003). Caffeine enhances the expression of the angiotensin II Type 2 receptor mRNA in BeWo cell culture and in the rat placenta.
  60. (1985). Caffeine in human milk and in serum of breast-fed infants.
  61. (1976). Caffeine in plasma and saliva by a radioimmunoassay procedure.
  62. (1979). Caffeine in pregnancy.
  63. (2006). Caffeine induces apoptosis of human umbilical vein endothelial cells through the caspase-9 pathway.
  64. (1998). Caffeine intake and low birth weight: a population-based case-control study.
  65. (1998). Caffeine intake and pregnancy outcomes: a meta-analytic review. Cadernos de Saude Publica
  66. (2007). Caffeine intake and small-for-gestational-age birth: modifying effects of xenobiotic-metabolising genes and smoking. Paediatr Perinat Epidemiol
  67. (2000). Caffeine intake and the risk of first-trimester spontaneous abortion.
  68. (1994). Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms.
  69. (2006). Caffeine metabolites in umbilical cord blood, cytochrome P-450 1A2 activity, and intrauterine growth restriction.
  70. (1995). Caffeine pharmacokinetics in obesity and following significant weight reduction.
  71. (1988). Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology (Berl)
  72. (1996). Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.
  73. (1978). Caffeine--its identity, dietary sources, intake and biological effects.
  74. (1983). Caffeine-induced limb malformations: description of malformations and quantitation of placental transfer.
  75. (1998). Caffeine, coffee and health.
  76. (1993). Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos
  77. (1984). Caffeine: a model compound for measuring liver function.
  78. (2007). Can we trust national smoking prevalence figures? Discrepancies between biochemically assessed and selfreported smoking rates in three countries.
  79. (1995). Case-control study of caffeinated beverages and preterm delivery.
  80. (1971). Cellular changes during placental and fetal growth.
  81. (2004). Changes in caffeine consumption as a signal of pregnancy.
  82. (2000). Changes in proliferative potential, apoptosis and Bcl-2 protein expression in cytotrophoblasts and syncytiotrophoblast in human placenta over the course of pregnancy.
  83. (1988). Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.
  84. (1992). Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos
  85. (1974). Chromosomal and other genetic influences on birth weight variation. Amsterdam: Elsievier-Excerpta Medica North.
  86. (2005). Chromosomal instability in amniocytes from fetuses of mothers who smoke.
  87. (1963). Chronic Fetal Distress and Placental Insufficiency.
  88. (1991). Chronic hypertension, cigarette smoking, and abruptio placentae.
  89. (1995). Cigarette smoking and clinically significant drug interactions.
  90. (1998). Cigarette smoking as a risk factor for ectopic pregnancy.
  91. (1991). Cigarette smoking during pregnancy in relation to placenta previa.
  92. (2008). Cigarette smoking during pregnancy.
  93. (1972). Cigarette smoking in pregnancy: its influence on birth weight and perinatal mortality.
  94. (1991). Cigarette-smoking, tea and coffee-drinking, and subfecundity.
  95. (1992). Cigarette, alcohol, and coffee consumption and congenital-defects.
  96. (1992). Cigarette, alcohol, and coffee consumption and prematurity.
  97. (1992). Cigarette, alcohol, and coffee consumption and spontaneous abortion.
  98. (1992). Cigarettes, coffee, and preterm premature rupture of the membranes.
  99. (1983). Cimetidine inhibits theophylline clearance in patients with chronic obstructive pulmonary disease: a study using stable isotope methodology during multiple oral dose administration.
  100. (1990). Clinical Applications of Ultrasonic Fetal Measurements. Working party Report, British Institute of Radiology,
  101. (1998). Coffee consumption and risk of hospitalized miscarriage before 12 weeks of gestation.
  102. (1991). Coffee consumption, birth-weight, and reproductive failures.
  103. (2001). Coffee Flavor Chemistry.
  104. (1986). Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man.
  105. (1986). Comparison of fetal weight estimation formulas with and without head measurements.
  106. (1987). Comparison of tests used to distinguish smokers from nonsmokers.
  107. (1994). Complications of pregnancy in relation to maternal lipid peroxides, glutathione, and exposure to metals. Reprod Toxicol 8(3):217-224.
  108. (1988). Confounders contributing to the reported associations of coffee or caffeine with disease.
  109. (1960). Congenital malformations in offspring of mice treated with caffeine.
  110. (1993). Cotinine concentrations in semen, urine, and blood of smokers and nonsmokers.
  111. (1987). Cotinine validation of self-reported smoking in commercially run community surveys.
  112. (1992). Customized Antenatal Growth Charts.
  113. (2004). Customized fetal growth standards: Rationale and clinical application.
  114. (1996). CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine.
  115. (1991). Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise.
  116. (1990). Cytochrome P450IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. In: Biological reactive intermediates IV,
  117. (1982). Delayed elimination of caffeine by women in the last 2 weeks of pregnancy.
  118. (1987). Determinants of low birth weight: methodological assessment and meta-analysis.
  119. (1990). Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
  120. (2004). Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry: the use of metabolic ratios to assess CYP1A2 activity.
  121. (1986). Development of a competitive enzyme-linked immunosorbent assay for detecting cytomegalovirus antibody.
  122. (1978). Dietary cravings and aversions during pregnancy.
  123. (1995). Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man.
  124. (2001). Differences in flexibility of active sites of cytochromes P450 probed by resonance Raman and UV-Vis absorption spectroscopy.
  125. (1998). Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study.
  126. (2003). Does caffeine and alcohol intake before pregnancy predict the occurrence of spontaneous abortion? Hum Reprod 18(12):2704-2710.
  127. (1995). Does coffee consumption increase the risk of reproductive adversities?
  128. (1997). Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for pre-eclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters.
  129. (1986). Dose-dependent kinetics of theophylline.
  130. (1988). Dose-response of birth weight to various measures of maternal smoking during pregnancy.
  131. (2002). Effect of caffeine exposure during pregnancy on birth weight and gestational age.
  132. (1997). Effect of caffeine intake during pregnancy on birth weight.
  133. (1991). Effect of levonorgestrel and ethinyl estradiol and their combination on biotransformation reactions.
  134. (1986). Effect of passive smoking on birth-weight.
  135. (1990). Effect of prenatal alcohol exposure on growth and morphology of offspring at 8 months of age.
  136. (1978). Effect of smoking on caffeine clearance.
  137. (1989). Effect of theophylline and adenosine on eosinophil function. Am Rev Respir Dis
  138. (1981). Effect of theophylline on prostaglandin E release from renal medullary tissue in rat (author's transl).
  139. (1985). Effect of theophylline on respiratory muscle function. Chest 88(Suppl 2):91S-97S.
  140. (2003). Effects of caffeine on human health.
  141. (1991). Effects of caffeine with repeated dosing.
  142. (1996). Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism.
  143. (2007). Effects of maternal smoking in pregnancy on prenatal brain development. The Generation R Study.
  144. (2000). Effects of symmetric and asymmetric fetal growth on pregnancy outcomes.
  145. (1983). Effects of tobacco smoking and oral contraceptive use on theophylline disposition.
  146. (1989). Effects on birth weight of smoking, alcohol, caffeine, socioeconomic factors, and psychosocial stress.
  147. (1993). Effects on birthweight of alcohol and caffeine consumption during pregnancy.
  148. (1991). Effects on birthweight of alcohol and caffeine consumption in smoking women.
  149. (1971). Emptying and absorption of caffeine from the human stomach.
  150. (2003). Endocrine-related causes and consequences of intrauterine growth retardation.
  151. (1971). Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.
  152. (1971). Enzymo-immunological determination of proteins with the aid of immunoadsorbants and enzyme-labelled antigens.
  153. (1994). Epidemiological correlates of preterm premature rupture of membranes.
  154. (1999). Estimation of cytochrome P-450CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
  155. (1996). Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
  156. (1987). Evidence for A1 and A2 adenosine receptors in guinea pig trachea.
  157. (1985). Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers.
  158. (2004). Factors contributing to the outcome of oxidative damage to nucleic acids.
  159. (2007). FASD: what types of intervention and rehabilitation are useful?
  160. (1998). Fetal alcohol abuse syndrome.
  161. (2004). Fetal alcohol syndrome prevention in Washington State: evidence of success.
  162. (2002). Fetal alcohol syndrome prevention research.
  163. (1999). Fetal amino acid and enzyme levels with maternal smoking.
  164. (1965). Fetal Development as Determined by Ultrasonic Pulse Echo Techniques.
  165. (1988). Fetal growth and body composition.
  166. (1986). Fetal growth and moderate drinking in early pregnancy.
  167. (2006). Fetal growth restriction: The etiology.
  168. (1989). Fetal Growth: Intrauterine growth retardation. In: Fetal -Maternal Medicine, (eds): Creasy & Resnik.
  169. (1996). Final Report on the reproductive toxicity of caffeine (CAS#58-08-2) administered by gavage to Sprague-Dawley rats. National Institute of Environmental Health Services.
  170. (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
  171. (1992). Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine.
  172. (1998). Formation and retention of cotinine during placental transfer of nicotine in human placental cotyledon.
  173. (1999). Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine.
  174. (1988). Further evidence for the effect of passive smoking on neonates.
  175. (1999). Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans.
  176. (2003). Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.
  177. (1989). Genetic polymorphisms of drugmetabolizing enzymes: molecular mechanisms.
  178. (1989). Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease.
  179. (1993). Health education for pregnant smokers: its behavioral impact and cost benefit.
  180. (2003). Health Survey for England,
  181. (2002). Heterogeneity in assessing self-reports of caffeine exposure: implications for studies of health effects.
  182. (2003). High caffeine consumption in the third trimester of pregnancy: gender-specific effects on fetal growth. Paediatr Perinatal Epidemiol 17(4):324-331.
  183. (1979). High Performance Liquid Chromatography. Ed: Knox JH.
  184. (1997). Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev
  185. (1989). Human cytochrome P450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines.
  186. (1982). Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration. Drug Metab Dispos
  187. (1990). Human Nacetylation genotype determination with urinary caffeine metabolites.
  188. (2003). Identification of a novel splice-site mutation in the CYP1A2 gene.
  189. (1996). Idiopathic fetal growth restriction: a pathophysiologic approach.
  190. (1980). Impaired elimination of caffeine by oral contraceptive steroids.
  191. (1984). Impaired fetal growth: ultrasonic evaluation and clinical management.
  192. (1985). Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives:
  193. (1993). Improved prediction of preeclampsia by two-stage screening of uterine arteries using the early diastolic notch and color Doppler imaging.
  194. (2002). Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation.
  195. (1997). Increased placental apoptosis in intrauterine growth restriction.
  196. (1998). Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test.
  197. (1993). Infant mortality revisited.
  198. (1985). Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man. Drug Metab Dispos 13(5):598-601.
  199. (1967). Influencing of pre- and postnatal development by maternal body weight and height as demonstrated on the results of reciprocal ovum transplantations between dwarf and large domestic swine.
  200. (1982). Inhibition of acetylcholine turnover rate in rat hippocampus and cortex by intraventricular injection of adenosine analogs.
  201. (1983). Inhibition of caffeine elimination by short-term ethanol administration.
  202. (1993). Inhibitory Effect of Grapefruit Juice and the Active Component Naringenin on
  203. (1992). Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro.
  204. (1995). Integrating smoking cessation into routine public prenatal care: the Smoking Cessation in Pregnancy project.
  205. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.
  206. (1992). Intra-individual variability of caffeine elimination in healthy subjects.
  207. (1987). Intrauterine growth and gestational duration determinants.
  208. (2002). Intrauterine growth restriction.
  209. (1971). Intrauterine growth retardation. Clinicopathologic findings in 233 consecutive infants.
  210. (1987). Is moderate drinking during pregnancy associated with an increased risk for malformations? Pediatrics 80(3):309-314.
  211. (1976). Letter: Caffeine accumulation associated with alcoholic liver disease.
  212. (2005). Life-long echoes--a critical analysis of the developmental origins of adult disease model.
  213. (2002). Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther
  214. (1997). Low-to-moderate gestational alcohol use and intrauterine growth retardation, low birthweight, and preterm delivery.
  215. (1987). Lung cancer and passive smoking: association of an artefact due to misclassification of smoking habits?
  216. (1984). Maternal alcohol consumption and birth weight. How much drinking during pregnancy is safe?
  217. (2006). Maternal caffeine consumption and fetal death: a case-control study in Uruguay. Paediatr Perinat Epidemiol
  218. (1996). Maternal caffeine consumption and spontaneous abortion: a prospective cohort study.
  219. (2008). Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study.
  220. (2001). Maternal caffeine intake and intrauterine growth retardation.
  221. (1985). Maternal caffeine use before, during and after pregnancy and effects upon offspring.
  222. (1991). Maternal cigarette smoking and the risk of tubal pregnancy.
  223. (2003). Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study.
  224. (2002). Maternal serum caffeine metabolites and small-for-gestational age birth.
  225. (1999). Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion.
  226. (1997). Maternal smoking and urinary organ malformations.
  227. (1997). Maternal smoking during pregnancy and limb reduction malformations in Sweden.
  228. (1995). Maternal smoking, alcohol drinking, caffeine consumption, and fetal growth: results from a prospective study.
  229. (2005). Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry.
  230. (1990). Measurement of current exposure to environmental tobacco smoke.
  231. (2004). Measuring tobacco smoke exposure: quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods.
  232. (1983). Metabolism of caffeine by mouse liver microsomes: GSH or cytosol causes a shift in products from 1,3,7-trimethylurate to a substituted diaminouracil.
  233. (1966). Method of antigen and antibody labelling with enzymes and its immunodiffusion application.
  234. (1991). Miscarriage, caffeine, and the epiphenomena of pregnancy: the causal model.[see comment][comment].
  235. (1988). Misclassification of smoking habits and passive smoking: A review of the evidence.
  236. (2003). Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
  237. (1993). Moderate caffeine use and the risk of spontaneous abortion and intrauterine growth retardation.[see comment].
  238. (1998). Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reprod Toxicol
  239. (2007). Morphological and biological effects of maternal exposure to tobacco smoke on the feto-placental unit. Early Hum Dev 83(11):699-706.
  240. (1985). Morphometric evaluation of the microvillous surface enlargement factor in the human placenta from mid-gestation to term.
  241. (1983). New doppler technique for assessing uteroplacental blood flow.
  242. (1982). No association between coffee consumption and adverse outcomes of pregnancy.
  243. (2000). Onset of maternal arterial blood flow and placental oxidative stress - A possible factor in human early pregnancy failure.
  244. (1955). Organisation
  245. (1994). Panfried meat containing high levels of heterocyclic aromatic amines but low levels of polycyclic aromatic hydrocarbons induces cytochrome P4501A2 activity in humans.
  246. (1990). Paraxanthine displaces the binding of [3H]SCH 23390 from rat striatal membranes.
  247. (1989). Paraxanthine metabolism in humans: determination of metabolic partial clearances and effects of allopurinol and cimetidine.
  248. (1994). Parental alcoholism and early child development.
  249. (2008). Parental characteristics as predictors of birthweight.
  250. (1962). Passage of caffeine into human gonadal and fetal tissue.
  251. (1995). Passive and active maternal smoking as measured by serum cotinine: the effect on birthweight.
  252. (1995). Passive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. II. Effects on neurodevelopment at age 5 years.
  253. (1993). Paternal smoking and birthweight in Shanghai.
  254. (1983). Pharmacodynamics of the diuretic effects of aminophylline and acetazolamide alone and combined with furosemide in normal subjects.
  255. (2004). Pharmacogenetics of the cytochromes P450.
  256. (1979). Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
  257. (1993). Pharmacokineticpharmacodynamic modeling of caffeine: tolerance to pressor effects.
  258. (1983). Pharmacokinetics of caffeine during and after pregnancy.
  259. (2006). Phenotypes of fetal growth. Personal Communication.
  260. (1994). Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.
  261. (1995). Physical Status: the use and interpretation of anthropometry. In:
  262. (1973). Physicochemical factors in maternal-fetal distribution of drugs.
  263. (1975). Physiological disposition of caffeine.
  264. (1997). Placental apoptosis in normal human pregnancy.
  265. (1978). Placental transfer of lead, mercury, cadmium, and carbon monoxide in women. II. influence of some epidemiological factors on the frequency distributions of the biological indices in maternal and umbilical cord blood.
  266. (1981). Plasma and salivary pharmacokinetics of caffeine in man.
  267. (1992). Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 98:69-74.
  268. (2003). Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.
  269. (1991). Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice.
  270. (1992). Prediction of the small for gestational age infant: which ultrasonic measurement is best?
  271. (2002). Pregnancy hormone metabolite patterns, pregnancy symptoms, and coffee consumption.
  272. (2007). Pregnancy loss.
  273. (2003). Pregnancy outcomes associated with intrauterine growth restriction.
  274. (1993). Prenatal alcohol exposure and longterm developmental consequences.
  275. (2003). Prenatal smoke exposure alters growth in limb proportions and head shape in the midgestation human fetus.
  276. (1981). Prolonged half-life of caffeine in healthy tem newborn infants.
  277. (1988). Purinergic receptors in the brainstem mediate hypotension and bradycardia.
  278. (1990). Quinolone Inhibition of Cytochrome-P-450-Dependent Caffeine Metabolism in Human Liver-Microsomes. Drug Metabol Dispos 18(6):1005-1010.
  279. (1992). Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities.
  280. (1997). Rate of caffeine metabolism and risk of spontaneous abortion.
  281. (2005). Reduced docosahexaenoic acid synthesis may contribute to growth restriction in infants born to mothers who smoke.
  282. (1975). Relation between tobacco smoking of pregnant women and body size of their progeny: a compilation and synthesis of published studies.
  283. (1970). Relation of birth weight, gestational age, and the rate of intrauterine growth to perinatal mortality.
  284. (1996). Relation of caffeine intake and blood caffeine concentrations during pregnancy to fetal growth: prospective population based study.
  285. (1993). Relation of caffeine intake during pregnancy to intrauterine growth retardation and preterm birth.[see comment].
  286. (1992). Reproductive effects of caffeine: a review and theoretical analysis.
  287. (2004). Restricted fetal growth in sudden intrauterine unexplained death.
  288. (1990). Risk factors for preterm premature rupture of the fetal membranes.
  289. (1986). Role of aromatic amine acetyltransferase in human colorectal cancer.
  290. (1995). Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity.
  291. (2006). Royal College of Obstetricians and Gynaecologists.
  292. (2000). Saliva cotinine levels in smokers and nonsmokers.
  293. (2001). School difficulties in 20-yearolds who were born small for gestational age at term in a regional cohort study.
  294. (2004). Science and Education and Tobacco Control Resource Centre.
  295. (1988). Second-trimester serum cotinine levels in nonsmokers in relation to birth weight.
  296. (1982). Selected birth defects in relation to caffeine-containing beverages.
  297. (2005). Self-reported smoking, cotinine levels, and patterns of smoking in pregnancy. Paediatr Perinat Epidemiol
  298. (1994). Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
  299. (1980). Simultaneous determinations by theophylline and its major metabolites in urine by reversed-phase ionpair high-performance liquid chromatography.
  300. (1987). Sonographic detection of smoking-related decreased fetal growth.
  301. (1998). Spectral analyses of cytochromes P450.
  302. (1994). Spontaneous abortion in a hospital population: are tobacco and coffee intake risk factors?
  303. (2002). SRNT Subcommittee on Biochemical Verification.
  304. (1992). Stability of salivary cotinine sent through the U.S. mail for verification of smoking status.
  305. (2001). Statement on the reproductive effects of caffeine. Department of Health.
  306. (2008). Statistics on smoking: England 2006. London. http://www.statistics.gov.uk/cci/nugget.asp?id=313 Organisation of Teratology Information Specialists.
  307. (1991). Structure and function of A1 adenosine receptors.
  308. (1993). Structureactivity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
  309. (1998). Survey of caffeine and other methylxanthines in energy drinks and other caffeine-containing products (updated). Food Surveillance Information Sheet No.
  310. (1970). Swedish standard curves for intra-uterine growth.
  311. (2005). Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
  312. (1969). Teratogenicity of caffeine in mice related to its mode of administration.
  313. (1999). The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review.
  314. (1987). The association between low birth weight and caffeine consumption during pregnancy.
  315. (1995). The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age.
  316. (2001). The associations of maternal caffeine consumption and nausea with spontaneous abortion.
  317. (1982). The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Thera 32(2):261-269.
  318. (1992). The changing pattern of fetal death,
  319. (1979). The clinical prediction of intrauterine growth retardation.
  320. (1983). The CO2 breath tests as monitors of the cytochrome P450 dependent mixed function monooxygenase system.
  321. (2002). The complexity of coffee.
  322. (1983). The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
  323. (1985). The contribution of low birth weight to infant mortality and childhood morbidity.
  324. (1981). The disposition of caffeine during and after pregnancy.
  325. (1983). The effect of caffeine on placental and fetal blood-flow in human-pregnancy.
  326. (1994). The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.
  327. (1996). The effect of liver disease on urine caffeine metabolite ratios.
  328. (1996). The effect of maternal drinking before conception and in early pregnancy on infant birthweight. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood.
  329. (1993). The effect of moderate maternal alcohol consumption on birth weight and gestational age in a low risk population. Early Hum Dev
  330. (2003). The effect of smoking and caffeine on the fetus and placenta in pregnancy.
  331. (1988). The effect of smoking on caffeine elimination: implications for its use as a semiquantitative test of liver function.
  332. (1968). The establishment of a cell line of human hormonesynthesizing trophoblastic cells in vitro.
  333. (1953). The fate of caffeine in man and a method for its estimation in biological material.
  334. (1990). The fetal and infant origins of adult disease.
  335. (1978). The genetics of birth weight. In: Human Growth: Principles and Perinatal Growth, (eds): Faulkner F and Tanner JM.
  336. (1983). The health consequences of caffeine.
  337. (1955). The inheritance of human birth weight.
  338. (1996). The maternal and fetal physiologic effects of nicotine.
  339. (1938). The maternal effects on growth and conformation in Shire-Shetland pony crosses. In:
  340. (1967). The physiological response of the vessels of the placental bed to normal pregnancy.
  341. (1990). The relationship of abruptio placentae with maternal smoking and small for gestational age infants.
  342. (1986). The role of pituitary hormones, growth factors and insulin in the regulation of fetal growth.
  343. (1993). The use of caffeine for enzyme assays: a critical appraisal.
  344. (1994). The validity of self-reported smoking: a review and meta-analysis.
  345. (1990). The value of Doppler assessment of the uteroplacental circulation in predicting preeclampsia or intrauterine growth retardation.
  346. (1995). Tobacco smoking and the uterine cervix: cotinine in blood, urine and cervical fluid.
  347. (1981). Tolerance to the humoral and hemodynamic effects of caffeine in man.
  348. (2003). Unexplained stillbirths: An investigation of the clinically relevant conditions at the time of fetal death.
  349. (2002). Update on caffeine consumption, disposition and action.
  350. (1991). Use Of Caffeine Metabolite Ratios To Explore CYP1A2 And Xanthine-Oxidase Activities. Clin Pharmacol Ther 50(5):508-519.
  351. (1987). Utero-placental blood flow velocity waveforms as predictors of pregnancy-induced hypertension.
  352. (1983). Uteroplacental arterial changes related to interstitial trophoblast migration in early human pregnancy.
  353. (1985). Uteroplacental blood flow velocity-time waveforms in normal and complicated pregnancy.
  354. (1983). Validation of self-reported smoking behavior: biochemical analyses of cotinine and thiocyanate.
  355. (2008). Validity of self-reported smoking status: Comparison of patients admitted to hospital with acute coronary syndrome and the general population.
  356. (1992). Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2.
  357. (1987). What do we know about the risks of caffeine consumption in pregnancy?

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.